ORIGINAL RESEARCH article
Front. Cell Dev. Biol.
Sec. Cell Growth and Division
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1681065
Modulation of the Cytoskeleton for Cancer Therapy
Provisionally accepted- DataSet Analysis LLC, 738471, San Francisco, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
ABSTRACT Introduction: All degenerative diseases are associated with impairment in intracellular trafficking. The highly dynamic organization and remodeling of the cellular cytoskeleton are dysfunctional in pathology and often lead to drug resistance. Successful analyses of the mechanisms of drug action require statistical analysis of large-scale readouts of molecular interactions at nanometer-scale resolution. The focus of our work is the automated extraction of unbiased information from time-lapse microscopy image series of the response of cytoskeletal meshworks, intracytoplasmic membranous networks, and vesicle trafficking to ex vivo drug treatment in cancer. We present the computer vision algorithms we have developed in this regard. Methods: We have performed cell biological profiling of cellular interactions and molecular mechanisms of pathogenesis and drug resistance. We are developing a platform for multifaceted analyses of intracellular and intercellular dynamics in patient-derived cultures. We aim to correlate our analyses with patterns of genetic and epigenetic variations in order to anticipate drug resistance and unfavorable treatment outcome. While we have established organoid cultures from solid tumor samples, we will perform preclinical and clinical analyses in a clinically-relevant model system in kidney organoids obtained from patient urine samples for which we will perform sequencing of long and small RNAs and will measure the expression levels of microtubule (MT) regulators and other cytoskeletal modulators. We label MT ends and will label other cellular components, such as actin, E-cadherin, cytoplasmic dynein, mitochondria, lysosomes, or exosomes, depending on the tumor type and disease stage. Our technology allows us to build a medical digital twin. Results: We report new function of the MT-stabilizing drug paclitaxel and the MT-destabilizing drug vinorelbine, which elucidate mechanisms beyond the canonical function of these tubulin inhibitors. We present new analysis results on patient stratification using non-invasive biomarkers, such as urinary small RNA. We identified dysregulated MT-regulating genes in colorectal cancer organoids that can be linked to spindle rotation during mitosis and resistance to MT-stabilizing drugs. The paper provides new results from our work with patient-derived cells cultured as organoids and the analysis of cancer vulnerabilities in the context of precision medicine.
Keywords: microtubule dynamics, solid tumors, Drug Resistance, Resistance disease, Sensitizing tumors
Received: 06 Aug 2025; Accepted: 22 Sep 2025.
Copyright: © 2025 Matov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Aleandre Matov, alexandre.matov@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.